Radiological and pathological assessment of response to neoadjuvant CDK4/6 inhibitor and endocrine treatments in a real-life setting—initial results
| Autor: | Leena Tiainen, Maija Tervo, Irina Rinta-Kiikka, Arja Jukkola, Teemu Tolonen, Niina Mäenpää, Annukka Salminen, Otso Arponen, Mikko Moisander, Antti Sassi |
|---|---|
| Přispěvatelé: | Tampere University, Department of Oncology, Clinical Medicine, Department of Radiology, Department of Pathology |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Chemotherapy response medicine.diagnostic_test biology Kinase business.industry medicine.medical_treatment Magnetic resonance imaging General Medicine 3126 Surgery anesthesiology intensive care radiology Real life setting cyclin-dependent kinase Cyclin-dependent kinase Radiological weapon Internal medicine medicine biology.protein magnetic resonance imaging Endocrine system Original Article business Pathological |
| Zdroj: | Acta Radiologica Open |
| ISSN: | 2058-4601 |
| DOI: | 10.1177/20584601211030660 |
| Popis: | Background Neoadjuvant endocrine therapy is an alternative to neoadjuvant chemotherapy in women with inoperable luminal-like breast cancers. Neoadjuvant cyclin-dependent kinase 4/6 inhibitor treatment combined with endocrine treatment (CDK4/6I + E) is interesting given the combination’s utility in the treatment of metastatic breast cancer. Currently, the literature on the radiological response evaluation of patients treated with neoadjuvant CDK4/6I + E in a real-life setting is scarce. Purpose To conduct a radiological response evaluation of patients treated with neoadjuvant CDK4/6I + E in a real-life setting. Material and methods We retrospectively reviewed clinical, pathological, and radiological findings of six patients with luminal-like breast cancers treated with neoadjuvant CDK4/6I + E treatment. The radiological neoadjuvant CDK4/6I + E response was evaluated with the RECIST 1.1 criteria and the pathological residual disease was assessed using the Residual Cancer Burden (RBC) criteria. Results None of the patients achieved a complete radiological magnetic resonance imaging (MRI)–determined response or a complete pathological response; three (50%) patients had a partial radiological response; in the three others, the disease remained stable radiologically. All of the tumors were rendered susceptible to surgical treatment. Two out of six (33.3%) patients had a moderate response (RBC-II); four (66.7%) had an extensive residual disease (RBC-III) in the final surgical sample. Conclusion Although none of the patients achieved a pathologically complete response, neoadjuvant CDK4/6I + E treatment rendered all tumors operable. MRI appears to be reliable in the assessment of the neoadjuvant CDK4/6I + E treatment response in a real-life setting. Larger studies are warranted to confirm these results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|